Stock 4127 TIEN LIANG BIOTECH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tien Liang BioTech Co., Ltd.

Equities

4127

TW0004127006

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-05-27 pm EDT 		5-day change 1st Jan Change
41.8 TWD -7.93% Intraday chart for Tien Liang BioTech Co., Ltd. +2.58% +188.28%
Mar. 29 Tien Liang BioTech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Tien Liang BioTech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 475.9 431.5 512.5 677.2 707 663.5
Enterprise Value (EV) 1 473.8 476.7 570.7 691.5 700.5 592.2
P/E ratio -5.04 x -9.23 x -9.93 x 14.5 x 11.9 x 37.4 x
Yield - - - - - -
Capitalization / Revenue 0.89 x 0.99 x 1.19 x 1.19 x 1.34 x 1.44 x
EV / Revenue 0.89 x 1.09 x 1.32 x 1.21 x 1.33 x 1.29 x
EV / EBITDA -13.4 x -17.8 x -15.4 x 12.8 x 10.3 x 20.5 x
EV / FCF -5.21 x -14.7 x 202 x 33.4 x -154 x 10.5 x
FCF Yield -19.2% -6.78% 0.49% 2.99% -0.65% 9.57%
Price to Book 1.02 x 1.03 x 1.4 x 1.64 x 1.49 x 1.35 x
Nbr of stocks (in thousands) 45,760 45,760 45,760 45,760 45,760 45,760
Reference price 2 10.40 9.430 11.20 14.80 15.45 14.50
Announcement Date 4/1/19 3/31/20 3/31/21 3/30/22 3/31/23 3/29/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 533.8 435.9 431.1 571.3 528.5 460
EBITDA 1 -35.45 -26.72 -37.05 54.15 68.28 28.82
EBIT 1 -65.08 -43.42 -50.68 42.95 58.29 18.87
Operating Margin -12.19% -9.96% -11.76% 7.52% 11.03% 4.1%
Earnings before Tax (EBT) 1 -95.96 -41.76 -48.59 48.78 59.33 18.42
Net income 1 -94.5 -46.78 -51.64 46.6 59.48 17.73
Net margin -17.7% -10.73% -11.98% 8.16% 11.25% 3.85%
EPS 2 -2.065 -1.022 -1.128 1.018 1.300 0.3875
Free Cash Flow 1 -90.91 -32.33 2.823 20.7 -4.546 56.67
FCF margin -17.03% -7.42% 0.65% 3.62% -0.86% 12.32%
FCF Conversion (EBITDA) - - - 38.23% - 196.64%
FCF Conversion (Net income) - - - 44.42% - 319.57%
Dividend per Share - - - - - -
Announcement Date 4/1/19 3/31/20 3/31/21 3/30/22 3/31/23 3/29/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 45.2 58.2 14.2 - -
Net Cash position 1 2.12 - - - 6.44 71.3
Leverage (Debt/EBITDA) - -1.692 x -1.571 x 0.2623 x - -
Free Cash Flow 1 -90.9 -32.3 2.82 20.7 -4.55 56.7
ROE (net income / shareholders' equity) -18.6% -10.6% -13.1% 11.9% 13.4% 3.66%
ROA (Net income/ Total Assets) -4.89% -3.91% -4.97% 4.19% 5.47% 1.77%
Assets 1 1,934 1,198 1,038 1,111 1,087 1,000
Book Value Per Share 2 10.20 9.160 8.030 9.050 10.40 10.80
Cash Flow per Share 2 3.710 1.910 2.520 2.590 2.360 3.110
Capex 1 20.9 1.27 1.09 0.6 1.01 4.96
Capex / Sales 3.92% 0.29% 0.25% 0.1% 0.19% 1.08%
Announcement Date 4/1/19 3/31/20 3/31/21 3/30/22 3/31/23 3/29/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
TIEN LIANG BIOTECH CO., LTD. Stock Tien Liang BioTech Co., Ltd.
+188.28% 64.54M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.59% 727B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.89% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.66% 328B
ABBVIE INC. Stock AbbVie Inc.
+0.24% 277B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.47% 243B
NOVARTIS AG Stock Novartis AG
+7.35% 205B
ROCHE HOLDING AG Stock Roche Holding AG
-6.42% 203B
AMGEN INC. Stock Amgen Inc.
+4.23% 164B
PFIZER, INC. Stock Pfizer, Inc.
-1.70% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4127 Stock
  4. Financials Tien Liang BioTech Co., Ltd.